• Investors may be wondering if Clorox at around US$96.85 is pricing in too much pessimism, or if the market is overlooking its potential value.
• The share price has retreated recently, with a 5.9% decline over 7 days, 8.5% over 30 days, 4.0% year to date and 27.2% over the last year. The 3 year and 5 year returns sit at 33.8% and 38.0% declines, respectively.
• These moves have kept Clorox on many investors' watchlists, as the stock's pullback is prompting questions about whether sentiment has swung too far. The current setup makes it a useful case study for how price, expectations and valuation methods interact.
• Clorox currently has a value score of 5 out of 6. This sets the scene for comparing different valuation approaches later in this article and then looking at a way to pull them together into a clearer view of value.

Approach 1: Clorox Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows, then discounts them back to today to estimate what the business may be worth right now. For Clorox, the 2 Stage Free Cash Flow to Equity model uses recent Free Cash Flow of about $777.1 million as a starting point and then applies analyst estimates and extrapolated figures over the coming years.

The projections include $596 million in 2026 and $764 million in 2028. Further estimates extend out to 2035. Simply Wall St uses analyst inputs where available and then extrapolates beyond that horizon to build a full 10 year cash flow path. All of these projected cash flows are then discounted to today and combined with a terminal value.

On this basis, the model suggests an intrinsic value of about $145.82 per share, compared with the current share price of around $96.85. That implies the stock is 33.6% undervalued according to this DCF framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Clorox is undervalued by 33.6%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.

Approach 2: Clorox Price vs Earnings

For a profitable company like Clorox, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. A higher P/E often reflects stronger growth expectations or lower perceived risk, while a lower P/E can point to more cautious expectations or higher perceived risk.

Clorox currently trades on a P/E of about 15.5x. This sits below the Household Products industry average of roughly 18.6x and also below the peer group average of around 25.5x, suggesting the market is assigning a lower earnings multiple to Clorox than to many of its peers.

Simply Wall St calculates a Fair Ratio for Clorox of about 16.9x. This Fair Ratio is a proprietary estimate of what the P/E might be, given factors such as earnings growth, profit margins, industry, company size and specific risks. It can be more informative than simple peer or industry comparisons because it adjusts for these company specific characteristics rather than assuming one size fits all. Comparing the Fair Ratio of 16.9x with the actual P/E of 15.5x indicates the shares are trading below this Fair Ratio.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Clorox Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring your view of Clorox to life by tying a clear story about the business to specific forecasts for revenue, earnings, margins and a fair value, then comparing that fair value with the current price on Simply Wall St's Community page, where millions of investors share views. These numbers are updated automatically when fresh news or earnings arrive. For example, a cautious Clorox Narrative might lean closer to a US$94 fair value, while a more optimistic one could sit nearer US$154.92. Your own choice between those types of stories helps you decide whether the current price looks attractive, expensive or somewhere in between, based on assumptions you understand and agree with.

For Clorox, however, we will make it really easy for you with previews of two leading Clorox Narratives:

Each one turns the same set of facts into a different story about future earnings power, valuation and risk. Use them as guide rails, then decide which assumptions feel closest to your own view.

Fair value: about US$154.92 per share.

Implied undervaluation vs last close of US$96.85: roughly 37.5%.

Revenue growth assumption in the model: about 2.12%.

• Sees Clorox’s ERP and digital transformation as a major source of recurring cost savings and higher margins, with earnings expectations tied to those efficiency gains.
• Focuses on need based product development, GOJO integration and a broader B2B footprint as supports for future earnings and potential market share recovery.
• Assumes the market is willing to pay a higher future P/E multiple than today, with analyst targets up to US$166.00, and asks you to judge whether those earnings and multiples feel reasonable.

Fair value: about US$94.00 per share.

Implied overvaluation vs last close of US$96.85: roughly 3.0%.

Revenue growth assumption in the model: about 5.30%.

• Highlights risks from slow product refresh, heavier exposure to traditional formulas and tougher competition from private labels and online focused brands.
• Flags higher regulatory and environmental compliance costs, plus ongoing supply chain and tariff pressures, as potential constraints on future margins.
• Builds in a lower future P/E multiple than today, with a central price target of US$94.00, and emphasizes that execution on growth plans and integration efforts may limit upside.

If you want to see how your own expectations stack up against these bullish and bearish frameworks, you can review the full community narratives and supporting numbers for Clorox in one place, then decide where on that spectrum your view sits before you act on the current share price. To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Clorox on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Clorox? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.